Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brimonidine gel for post-acne erythema
IRCT20140212016557N11Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of brimonidine in Postinflammatory erythema (PIE) (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoint: Clinician score of post-acne erythema. Started Aug 2023; status: completed.
02
Drugs
brimonidine
03
Conditions
Postinflammatory erythema (PIE)
Beyond the preview
Go deeper on IRCT20140212016557N11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20140212016557N11.